Free tool
FAERS Monitor: Amvuttra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215515 or its brand name (Amvuttra, Vutrisiran Sodium). Reports on generic versions are filed under their own applications.
Reports
2,969
Serious
2,505
84% of reports
Hospitalization
1,203
Death reported
745
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death601
- hospitalisation367
- intentional dose omission262
- product dose omission issue168
- fall142
- fatigue122
- dyspnoea104
- cardiac failure94
- therapy interrupted94
- gait disturbance87
- arthralgia80
- asthenia80
- pain in extremity76
- ill-defined disorder75
- atrial fibrillation74
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 21 |
| 2023 | 367 |
| 2024 | 516 |
| 2025 | 868 |
| 2026 | 1,195 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intentional dose omissionSignal | 262 | 65.7 | 58.5 | 16,497 |
| hospitalisationSignal | 367 | 17.0 | 15.4 | 5,523 |
| therapy interruptedSignal | 94 | 9.3 | 7.6 | 692 |
| ill-defined disorderSignal | 75 | 8.8 | 7.0 | 508 |
| cardiac failureSignal | 94 | 8.3 | 6.8 | 598 |
| atrial fibrillationSignal | 74 | 5.4 | 4.3 | 261 |
| deathSignal | 601 | 4.9 | 4.6 | 1,967 |
| product dose omission issueSignal | 168 | 4.0 | 3.5 | 388 |
| gait disturbanceSignal | 87 | 3.2 | 2.6 | 132 |
| fallSignal | 142 | 3.0 | 2.6 | 193 |
| pain in extremity | 76 | 1.8 | 1.5 | 28 |
| asthenia | 80 | 1.5 | 1.2 | 13 |
| arthralgia | 80 | 1.4 | 1.1 | 8 |
| dyspnoea | 104 | 1.3 | 1.1 | 7 |
| fatigue | 122 | 1.1 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.